Abstract
We report the efficacy, tolerability and cost of erythocytoapheresis plus recombinant human erythropoietin (rHuEPO) in three patients with severe hereditary hemochromatosis (HH). Results indicate that this regimen could be a valid therapeutic alternative in complicated HH patients. Its cost, however, limits its use to patients whose clinical conditions prevent a proper phlebotomy regimen.
Publication types
-
Evaluation Study
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Combined Modality Therapy
-
Cytapheresis / economics
-
Cytapheresis / methods*
-
Erythropoietin / economics
-
Erythropoietin / therapeutic use*
-
Hemochromatosis / blood
-
Hemochromatosis / drug therapy
-
Hemochromatosis / genetics
-
Hemochromatosis / pathology
-
Hemochromatosis / therapy*
-
Hemochromatosis Protein
-
Histocompatibility Antigens Class I / genetics
-
Humans
-
Iron Overload / etiology
-
Iron Overload / therapy
-
Liver Cirrhosis / etiology
-
Male
-
Membrane Proteins / genetics
-
Middle Aged
-
Recombinant Proteins
-
Treatment Outcome
Substances
-
HFE protein, human
-
Hemochromatosis Protein
-
Histocompatibility Antigens Class I
-
Membrane Proteins
-
Recombinant Proteins
-
Erythropoietin